Zymeworks reports $122.7M net loss for 2024; Ziihera approval drives $25M milestone

Zymeworks Inc.

Revenue $76.3M in 2024 (vs $76.0M in 2023); net loss $122.7M vs $118.7M loss prior year.
Cash resources $324.2M at Dec 31, 2024; projected runway into 2H-2027 with anticipated regulatory milestones.
Ziihera (zanidatamab) FDA approved for HER2+ BTC in Nov 2024; initial net sales $1.1M; $25M milestone earned from Jazz.
Phase 1 studies initiated for ZW191 and ZW171; IND for ZW251 accelerated to mid-2025; ZW220 preparations paused.
Non-cash impairment charge of $17.3M for discontinuation of zanidatamab zovodotin; $14M milestone from GSK in Jan 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.